Design a novel 5HT2c agonist for the treatment of serotonin related disorders

被引：0
|
作者：
Liu, Kevin K-C. [1 ]
机构：
[1] Pfizer Inc, Discovery Chem, La Jolla, CA 92121 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2009年 / 238卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
80-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Psychopathological traits in patients with bulimia nervosa are associated to serotonin receptor 5HT2C and serotonin transporter 5HTT alleles
    Ribasés, M
    Mercader, J
    Gratacòs, M
    Badia, A
    Jiménez, L
    Solano, R
    Vallejo, J
    Fernández-Aranda, F
    Estivill, X
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2004, 130B (01): : 68 - 69
  • [22] Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity
    Yang, Ha Yun
    Tae, Jinsung
    Seo, Yong Wan
    Kim, Yoon Jung
    Im, Hye Yeon
    Choi, Gil Don
    Cho, Heeyeong
    Park, Woo-Kyu
    Kwon, Oh Seung
    Cho, Yong Seo
    Ko, Minkyung
    Jang, HyunSeo
    Lee, Jaeick
    Choi, Kihang
    Kim, Chan-Hwa
    Lee, Jiyoun
    Pae, Ae Nim
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 63 : 558 - 569
  • [23] Mutational analysis of the serotonin receptor 5HT2c in severe early-onset human obesity
    Gibson, WT
    Ebersole, BJ
    Bhattacharyya, S
    Clayton, P
    Farooqi, IS
    Sealfon, SC
    O'Rahilly, S
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2004, 82 (06) : 426 - 429
  • [24] Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders
    Lôo, H
    Daléry, J
    Macher, JP
    Payen, A
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2002, 28 (04): : 356 - 362
  • [25] Vilazodone: A 5-HT1A Receptor Agonist/Serotonin Transporter Inhibitor for the Treatment of Affective Disorders
    Dawson, Lee A.
    Watson, Jeannette M.
    CNS NEUROSCIENCE & THERAPEUTICS, 2009, 15 (02) : 107 - 117
  • [26] Lorcaserin: A novel, selective 5-HT2C-receptor agonist for the treatment of obesity
    Pauli, Maribeth
    Abdelghany, Sam
    FORMULARY, 2010, 45 (06) : 180 - 186
  • [27] 5HT2C receptor polymorphisms, weight gain, and clinical response to clozapine treatment
    Miller, DD
    Ellingrod, VL
    Holman, T
    Buckley, PF
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 273 - 273
  • [28] RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function
    Werry, Tim D.
    Loiacono, Richard
    Sexton, Patrick M.
    Christopoulos, Arthur
    PHARMACOLOGY & THERAPEUTICS, 2008, 119 (01) : 7 - 23
  • [29] Serotonin 5-HT2 Receptor AntagonistsPotential in the Treatment of Psychiatric Disorders
    Roman Stefanski
    Steven R. Goldberg
    CNS Drugs, 1997, 7 : 388 - 409
  • [30] Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders.
    Lôo, H
    Daléry, J
    Macher, JP
    Payen, A
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2003, 29 (02): : 165 - 171
12345